Author: Gränicher, Gwendal; Tapia, Felipe; Behrendt, Ilona; Jordan, Ingo; Genzel, Yvonne; Reichl, Udo
Title: Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production Cord-id: g91hoczu Document date: 2020_8_6
ID: g91hoczu
Snippet: Modified Vaccinia Ankara (MVA) virus is a promising vector for vaccination against various challenging pathogens or the treatment of some types of cancers. Because this vector is unable to replicate in human recipients, a high amount of virions per dose is required for vaccination and gene therapy. Upstream process intensification combining perfusion technologies, the avian suspension cell line AGE1.CR.pIX and the virus strain MVAâ€CR19 is an option to obtain very high MVA yields. Here we compa
Document: Modified Vaccinia Ankara (MVA) virus is a promising vector for vaccination against various challenging pathogens or the treatment of some types of cancers. Because this vector is unable to replicate in human recipients, a high amount of virions per dose is required for vaccination and gene therapy. Upstream process intensification combining perfusion technologies, the avian suspension cell line AGE1.CR.pIX and the virus strain MVAâ€CR19 is an option to obtain very high MVA yields. Here we compared different options for cell retention in perfusion mode using conventional stirredâ€tank bioreactors including an alternating tangential flow filtration system, an acoustic settler and an inclined settler. The last two options allowed continuous MVA virus harvesting. Furthermore, we studied hollowâ€fiber based bioreactors and an orbitalâ€shaken bioreactor in perfusion mode, both available for singleâ€use. Productivity for the virus strain MVAâ€CR19 was compared to results from batch and continuous production reported in literature. Our results demonstrate that MVA virus is highly stable at 37°C in cell culture so that cell retention devices are only required to maximize cell concentration but not for continuous harvesting. Using a stirredâ€tank bioreactor, a perfusion strategy during the whole run with working volume expansion after virus infection resulted in the highest yields. Overall, infectious MVA virus titers of 2.1–16.5 × 10(9) virions/mL were achieved in these intensified processes. Taken together, the study shows a novel perspective on highâ€yield MVA virus production in conventional bioreactor systems linked to various cell retention devices and addresses options for process intensification including fully singleâ€use perfusion platforms. This article is protected by copyright. All rights reserved
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date